Form 4: INBS CEO Simeonidis Granted 30,500 Restricted Shares

Intelligent Bio Solutions Inc. CEO Harry Simeonidis received 30,500 restricted common shares under the company's 2019 Long Term Incentive Plan, subject to vesting conditions.

Summary

• CEO Harry Simeonidis was granted a total of 30,500 restricted shares of Common Stock on March 18, 2026.
• 9,150 of these shares are subject to time-based vesting over 48 months.
• 21,350 shares are subject to joint performance-based and time-based vesting requirements.
• All granted shares are subject to forfeiture until vested.
• The company previously effected a 1-for-10 reverse stock split on December 15, 2025, which proportionally adjusted the reporting person's holdings and awards.
• Following these transactions, Harry Simeonidis beneficially owns 34,540 shares of Common Stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting standard executive compensation practices aimed at long-term alignment, though the prior reverse stock split could be a minor concern.

Positives

• The grant of restricted shares aligns the CEO's incentives with long-term shareholder value creation through time-based and performance-based vesting.
• The performance-based vesting component suggests a focus on achieving specific company goals.

Negatives

• The reverse stock split in December 2025, while a technical adjustment, can sometimes be perceived negatively by the market as it often follows a period of low stock price.

Risks

• The granted shares are subject to forfeiture until vested, meaning the CEO will only fully own them if vesting conditions (time and/or performance) are met.

Future Outlook

The filing indicates a long-term incentive plan with vesting periods extending 48 months, suggesting a focus on future performance and retention of key management.

Industry Context

StockSavvy.ai notes that equity grants to executives are a standard practice across industries to align management interests with shareholder value. The combination of time-based and performance-based vesting is a common structure designed to incentivize both retention and achievement of strategic objectives.

Comparison to Industry Standards

• The use of a Long Term Incentive Plan (LTIP) with restricted stock units (RSUs) is a common compensation practice for CEOs in publicly traded companies, comparable to structures seen at biotech firms like Moderna or pharmaceutical companies like Pfizer, which often tie executive compensation to multi-year performance and retention.
• The 48-month vesting period for time-based awards is within the typical range for executive equity grants, often seen in tech companies such as Microsoft or Google, aiming for long-term commitment.
• The inclusion of performance-based vesting is a best practice in corporate governance, similar to compensation plans at companies like Apple or Amazon, ensuring that a portion of executive compensation is directly linked to the achievement of specific operational or financial targets.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact through increased alignment of CEO incentives with long-term company performance and value creation.
• Employees: No direct impact mentioned, but a well-compensated and incentivized CEO can contribute to overall company stability and growth.

Next Steps

• The granted shares will vest over time (48 months for one portion) and based on performance for another portion.

Key Dates

Recommendation

This Form 4 reports a routine equity grant to the CEO as part of a long-term incentive plan, which is a standard compensation practice. While it aligns management's interests with shareholders, it does not present new information that would fundamentally alter the company's valuation or immediate prospects to warrant a "buy" or "sell" recommendation. The prior reverse stock split is a historical event. Therefore, a "hold" recommendation is appropriate as this filing provides no strong catalyst for a change in investment thesis.

Keywords

INBS, Intelligent Bio Solutions, Harry Simeonidis, Restricted Stock, Equity Grant, CEO Compensation, Form 4, Insider Trading, Long Term Incentive Plan, Reverse Stock Split